Extended Data Fig. 5: Longitudinal binding by dose of in vivo-expressed DMAb against SARS-CoV-2 Delta, Omicron BA.2 and BA.4/5 RBDs. | Nature Medicine

Extended Data Fig. 5: Longitudinal binding by dose of in vivo-expressed DMAb against SARS-CoV-2 Delta, Omicron BA.2 and BA.4/5 RBDs.

From: Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Extended Data Fig. 5

An anti-YTE antibody was used to capture DMAb from participant sera. Binding was detected with biotinylated Spike receptor binding domains (RBD). Graphs are plotted as area under the curve (AUC x 1000) for individual participants and the group mean is shown in navy blue.

Back to article page